Compare Novartis AG (NVS) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Ulta Beauty Inc — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Ulta Beauty Inc trades at $542.13 (market cap $23.59B). The key difference: Novartis AG is far larger — about 12.6× Ulta Beauty Inc's market cap, and Novartis AG pays a 3.02% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals.
| NVS | ULTA | |
|---|---|---|
Market Cap | $298.18B | $23.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $706.82 |
52-Week Low | $119.31 | $450.75 |
Enterprise Value | $339.50B | $25.67B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
ULTA stock trades at $565.15, up 4.89% in the last session, with a bullish technical outlook supported by moving averages and strong support at $547. The company reported Q1 2026 EPS of $7.74, beating estimates, but faces margin compression with net income margin declining to 10.63% in 2025. Recent news highlights the end of its Target partnership as a potential growth opportunity, per BofA analysis on July 29, 2026.
The stock offers upside to the consensus price target of $618.29, with 57% of analysts rating it a buy, but risks include competitive pressures and volatile cash flows, with net cash flow turning negative in 2025. Investors should weigh robust ROE of 47.45% against elevated P/B of 9.41 and RSI levels suggesting overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
